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Rewarding effects have been related to enhanced dopamine (DA) release in
corticolimbic and basal ganglia structures. The DAergic and endocannabinoid interaction
in the responses to reward is described. This study investigated the link between
endocannabinoid and DAergic transmission in the processes that are related to response
to two types of reward, palatable food and novelty. Mice treated with drugs acting on
endocannabinoid system (ECS) (URB597, AM251) or DAergic system (haloperidol) were
submitted to approach-avoidance conflict tasks with palatable food or novelty. In the same
mice, the cannabinoid type-1 (CB1)-mediated GABAergic transmission in medium spiny
neurons of the dorsomedial striatum was analyzed. The endocannabinoid potentiation by
URB597 magnified approach behavior for reward (food and novelty) and in parallel inhibited
dorsostriatal GABAergic neurotransmission. The decreased activity of CB1 receptor by
AM251 (alone or with URB597) or of DAergic D2 receptor by haloperidol had inhibitory
effects toward the reward and did not permit the inhibition of dorsostriatal GABAergic
transmission. When haloperidol was coadministered with URB597, a restoration effect on
reward and reward-dependent motor activity was observed, only if the reward was the
palatable food. In parallel, the coadministration led to restoring inhibition of CB1-mediated
GABAergic transmission. Thus, in the presence of simultaneous ECS activation and
inhibition of DAergic system the response to reward appears to be a stimulus-dependent
manner.
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INTRODUCTION
Survival strictly depends on the drive with which subjects seek
natural reinforcers, such as food, water, sex, and maternal
care. Converging electrophysiological, biochemical, and behav-
ioral evidence implicates the endocannabinoid system (ECS) in
the neurobiological events that attribute value to various types
of reinforcers (Maldonado et al., 2006; Marsicano and Lutz,
2006; Laricchiuta et al., 2012a,b). The ECS mediates the balance
between approach and avoidance behaviors toward stimuli in
humans (Van Laere et al., 2009) and rodents (Lafenêtre et al.,
2009; Laricchiuta et al., 2012a,b), the detailed mechanism of
which is unknown.
Most central ECS functions are mediated by cannabinoid
type-1 (CB1) receptors (Freund et al., 2003; Piomelli, 2003) that
presynaptically inhibit primarily glutamatergic and GABAergic
transmission, but also dopaminergic and cholinergic transmis-
sion (Matias and Di Marzo, 2007; Kano et al., 2009). Notably,
the reward effects of primary reinforcers or environmental stimuli
that are associated with food or drug intake have been related
to enhanced dopamine (DA) release in corticolimbic and basal
ganglia structures (Bassareo et al., 2002; Ito et al., 2002; Lupica
and Riegel, 2005). Thus, DA is a neurosignal that has been
evolutionarily adjusted to boost the organism toward reinforcer
(Alcaro and Panksepp, 2011).
There is increasing evidence that implicates a dynamic DAergic
and endocannabinoid interaction in neuronal, endocrine, and
metabolic responses to reward (Di Marzo et al., 2004; Fernández-
Ruiz et al., 2010). The inhibitory effects of the ECS against DAer-
gic neurons in mesolimbic structures have been hypothesized
to attribute the salience to reward. Supporting this model, CB1
antagonists impair the attribution of salience to a stimulus (De
Vries et al., 2001; Fattore et al., 2003). Further, the ECS has been
implicated in several neuropsychiatric conditions, including DA-
related disorders, such as schizophrenia (Emrich et al., 1997),
Parkinson disease (Maccarrone et al., 2003), and drug addiction
(Maldonado and Rodríguez de Fonseca, 2002). In these patholog-
ical conditions, involvement of the ECS likely reflects the activity
of reward circuitry, which comprises midbrain DAergic neurons
and their target structures (Berke and Hyman, 2000; Everitt and
Wolf, 2002).
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This study aimed to behaviorally and electrophysiologically
examine endocannabinoid and DAergic involvement in processes
that are related to seeking two types of reward: palatable food and
novelty. The interaction between the ECS and DAergic system in
processing salient information is attracting significant interest.
In this study, mice that were treated with drugs that act on
the ECS or DAergic system were subjected to approach-avoidance
conflict tasks with two rewards (food or novelty). In addition,
CB1-mediated GABAergic transmission in medium spiny neu-
rons of the dorsomedial striatum was analyzed. This area is the
ideal structure to study the interplay between the ECS or DAergic
systems, because it has a high density of CB1 and DAergic recep-
tors (Piomelli, 2003) and is critical in goal-directed behaviors
(Koob and Volkow, 2010).
MATERIALS AND METHODS
SUBJECTS
Young (32 ± 2 days) male C57BL/6JOlaHsd mice (Harlan, Italy)
were used. All animals were housed, 4 per cage, with food
(Mucedola 4RF21, Italy) and water ad libitum. The mice were kept
under a 12-h light/dark cycle with the lights coming on at 07:00 h,
controlled temperature (22–23◦C), and constant humidity (60 ±
5%). All efforts were made to minimize animal suffering and
reduce the number of animals that were used, per the European
Directive (2010/63/EU).
All animals (n = 10/group) included in the present study were
behaviorally tested in the Approach/Avoidance Y-Maze (A/A Y-
Maze) and the Open-Field test with novel object. Both tasks
permit to detect crucial components of animal behavior linked
to approach-avoidance motivation, as the tendency to explore,
respond to an environmental change or seek for reward and
novelty. In fact, the explorative drive represents the prerequisite of
the recognition and seeking for novel stimuli, crucial components
of approach and avoidance motivation.
Experimental procedures are shown in Figure 1.
FIGURE 1 | Procedures and global timing of experimental design.
C57BL/6J mice were tested in the Approach/Avoidance Y-Maze (A/A
Y-Maze) and in the Open Field (OF) test. At the end of behavioral testing,
Electrophysiological Recordings (ER) were performed from medium spiny
neurons of the dorsomedial striatum. Drugs were administered before S3
of A/A Y-Maze and OF task as well as before ER.
BEHAVIORAL TESTING: APPROACH/AVOIDANCE Y-MAZE (A/A Y-MAZE)
This test was performed as previously described (Laricchiuta et al.,
2012a,b). In particular, the apparatus consisted of a Plexiglas Y-
maze with a starting gray arm from which two arms (8 cm ×
30 cm × 15 cm) stemmed, arranged 90◦ to each other. A T-
guillotine door was placed at the end of the starting arm to prevent
the animal from returning to the start. An arm entry was defined
as four legs entering one of the arms. The two arms of choice
differed in color and brightness—one of the two arms had a
black and opaque floor and walls and no light inside, whereas
the other had a white floor and walls and was lit by a 16-W neon
lamp. Notably, the colored “furniture” and the neon lamp were
exchangeable between arms to alternate the position of the white
and black arms.
The apparatus was placed in a dim room that was lit by a
red light (40 W) and was cleaned thoroughly with 70% ethanol
and dried after each trial to remove scent cues. At the end of
each arm of choice, there was a blue chemically inert tube cap
(3 cm in diameter, 1 cm deep) that was used as a food tray.
The depth of the tray prevented mice from seeing the reward at
a distance but permitted easy reward—i.e., eating. Because the
appetites for palatable foods must be learned (Lafenêtre et al.,
2009), 1 week before the behavioral testing, the animals were
exposed to a novel palatable food (Fonzies, KP Snack Foods,
Munchen, Germany) in their home cages for three consecutive
days (Bassareo et al., 2002). Fonzies (8% protein, 33% fat, and
53% carbohydrate, for a caloric value of 541 kcal/100 gm) consist
of corn flour, hydrogenate vegetable fat, cheese powder, and
salt.
At the start of behavioral testing, the mice were subjected to a
1-day habituation phase in which all Y-Maze arms were opened to
encourage exploration of the maze without the presence of food.
The white and lit arm was placed on the right side of the apparatus
for the first 5 min and then on the left side for the subsequent
5 min. To increase the motivation to search for the reward, the
animals were slightly food-deprived by limiting access to food in
the 10 h before the test; this procedure did not result in any body
weight loss.
The testing phase (24 h after the habituation phase) comprised
two 10-trial sessions. In Session 1 (S1), the animal was placed in
the starting arm and could choose to enter one of the two arms,
both containing the same standard food reward. After eating, the
animal was allowed to stand in its cage for a 1-min intertrial
interval. At the end of each trial, the reward was replaced. The
spatial position of each arm (black and dark or white and lit) was
sequentially exchanged and side-balanced during the entire test to
exclude any preference with regard to side.
During Session 2 (S2), starting 24 h after S1, the white arm was
rewarded with the highly palatable food (Fonzies), and the black
arm was rewarded with the standard food pellet.
Forty-eighty hours after S2, the animals were retested (S3) in
the A/A Y-Maze per the S2 protocol.
The parameters were: white choices, the frequency of entries
into the white arm, to study the approach and avoidance com-
ponents; entry latency in the arm of choice, to study the loco-
motor component; and defecation boluses, to evaluate anxiety
levels.
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BEHAVIORAL TESTING: OPEN-FIELD (OF) TEST WITH NOVEL OBJECT
Forty-eighty hours after the end of the A/A Y-Maze task, the OF
test was performed. The apparatus, placed in a dimly lit (red light
40 W) and soundproof cubicle room, consisted of a circular arena
(diameter 60 cm) that was delimited by a pale gray wall that was
20 cm high. During Session 1 (S1), a single animal was allowed
to explore the empty open field, and its baseline level of activity
was measured. During Session 2 (S2), a new appealing object (a
gray plastic cone: height: 10 cm, diameter: 6 cm, with a circular
base: diameter: 9.5 cm) was inserted in the anxiogenic central
location of the arena. Thus, the response to change exhibited
by the animal in S2 is an index of its reaction to conflicting
situation.
Sessions lasted 10 min, and the intersession interval was 5 min.
The apparatus and object were cleaned thoroughly with 70%
ethanol and dried after each session to remove scent cues.
The entire test was recorded on a video camera that was
mounted on the ceiling. The video feed was relayed to a monitor
and processed through an image analyzer (Ethovision, Noldus,
Wageningen, the Netherlands).
The parameters that we considered were: total distance (in cm)
traveled in the arena and mean velocity, to study the explorative
and locomotor components; peripheral distance (expressed as
the percentage of total distance traveled in a 6-cm peripheral
annulus), freezing time and defecation boluses, to evaluate anxiety
levels; and contact times with the object, to study the approach-
avoidance components that were elicited by insertion of the new
appealing object in an anxiogenic central location of the wide
arena. Contact with the object was considered to take place when
the mouse’s snout touched it, or when the animal sniffed the
object for at least 1 s.
ELECTROPHYSIOLOGICAL RECORDINGS
Mice were killed by cervical dislocation under halothane anesthe-
sia. By using a vibratome, corticostriatal coronal slices (200 µm)
were prepared from brain fresh tissue and left recovered for
30 min in an Artificial CSF (ACSF) gassed with 95% O2–5% CO2.
The composition (in mM) of the control ACSF was: NaCl (126),
KCl (2.5), MgCl2 (1.2), NaH2PO4 (1.2), CaCl2 (2.4), Glucose (11),
NaHCO3 (25).
Whole-cell patch clamp recordings from single striatal neurons
were made as previously described (Centonze et al., 2007a,b; De
Chiara et al., 2010a,b; Laricchiuta et al., 2012b; Musella et al.,
2014). A single slice was transferred to a recording chamber and
submerged in a continuously flowing oxygenated ACSF (34◦C, 2–
3 ml/min). The striatum could be readily identified under low
power magnification, whereas individual neurons were visualized
in situ using a differential interference contrast (Nomarski) optical
system. This system employed an Olympus BX50WI (Japan)
non-inverted microscope with 40x water immersion objective
combined with an infra-red filter, a monochrome CCD camera
(COHU 4912), and a PC compatible system for analysis of images
and contrast enhancement (WinVision 2000, Delta Sistemi, Italy).
Recording pipettes were advanced towards individual striatal cells
in the slice under positive pressure and visual control (WinVision
2000, Delta Sistemi, Italy) and, on contact, tight GΩ seals were
made by applying negative pressure. The membrane patch was
then ruptured by suction and membrane current and poten-
tial monitored by using an Axopatch 1D patch clamp amplifier
(Molecular Devices, Foster City, CA, USA). Whole-cell access
resistances measured in voltage clamp were in the range of 5–
20 MΩ.
Whole-cell patch clamp recordings were made with borosili-
cate glass pipettes (1.8 mm o.d.; 2–3 MΩ), in voltage clamp mode,
at the holding potential (HP) of−80 mV.
To detect spontaneous GABAA-mediated inhibitory postsy-
naptic currents (sIPSCs), the intraelectrode solution comprised
(in mM): CsCl (110), K+-gluconate (30), ethylene glycol-bis
(ß-aminoethyl ether)-N,N,N′,N′-tetra-acetic acid (EGTA; 1.1),
HEPES (10), CaCl2 (0.1), Mg-ATP (4), and Na-GTP (0.3). MK-
801 (30 µM) and CNQX (10 µM) were added to the external
solution to block NMDA and non-NMDA glutamate receptors,
respectively.
sIPSCs were stored using a P-CLAMP 9 (Molecular Devices,
Foster City, CA, USA) and analyzed offline on a personal com-
puter with Mini Analysis 5.1 (Synaptosoft, Leonia, NJ, USA).
The offline analysis was performed on sIPSCs that were recorded
during fixed times (5–10 samples of 2–3 min each, recorded every
2–3 min). Only cells that had stable frequencies (<20% change in
the control samples) were considered.
HU210, used in the slices, was first dissolved in DMSO and
then in ACSF to the desired final concentration. DMSO alone was
used as the control. The concentrations (in µM) of the various
drugs were as follows: CNQX (10), HU210 (1), and MK-801 (30)
(Tocris, Bristol, UK).
For the electrophysiological data, “n” refers to the number of
cells. One to six neurons per animal were recorded. Electrophysi-
ological measures were obtained by pooling data from at least five
animals in each group.
DRUGS
All drugs were dissolved in vehicle (VHL) that comprised saline
solution with 10% DMSO and 5% Tween 80 and administered
at volume of 5 ml/kg of body weight. The animals in the URB
group (n = 10) were first intraperitoneally (i.p.) injected with the
fatty acid amide hydrolase (FAAH) inhibitor URB597 (0.3 mg/kg;
Alexis, USA) and then injected immediately after with the same
volume of VHL without drug. The animals in the AM group (n =
10) were injected i.p. first with the CB1 receptor inverse agonist
AM251 (1 mg/kg; Tocris, UK) and immediately after with the
same volume of VHL without drug. In the haloperidol (HAL)
group (n = 10), animals were injected i.p. first with the DAergic
D2 receptor antagonist haloperidol (0.25 mg/kg; Sigma, Italy)
and immediately after with the same volume of VHL without
drug. The URB+HAL group (n = 10) was injected i.p. with
URB597 (0.3 mg/kg) and haloperidol (0.25 mg/kg). The animals
in the URB+AM group (n = 10) were injected i.p. with URB597
(0.3 mg/kg) and AM251 (1 mg/kg). The control animals (n = 10)
received the same volume of VHL i.p. twice.
Further, we examined 10 animals that were injected i.p. with
AM251 (1 mg/kg) and haloperidol (0.25 mg/kg), but it was not
possible to report their results, because they were completely
inhibited and remained motionless, failing to seek the reward in
either behavioral test.
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Drugs were administered at dosages which are reported to
have effects on reward-, novelty- and emotion-related behaviors.
Namely, the selection of URB597 dosage at 0.3 mg/kg was based
on our previous behavioral and electrophysiological results (Rossi
et al., 2010; Laricchiuta et al., 2012b, 2013). The same dosage was
used by Naderi et al. (2008) to investigate URB597 behavioral
effects on anxiety, as well as by Fegley et al. (2005) to characterize
its neurochemical profile.
The selection of AM251 dosage at 1 mg/kg was based on
behavioral results on locomotor- (Eisenstein et al., 2010), anxiety-
(Umathe et al., 2009) and reward- (Xi et al., 2008) related effects.
The same dosage was used by Maione et al. (2013) to investigate
AM251 neurochemical properties.
The selection of haloperidol dosage at 0.25 mg/kg was based on
behavioral results on locomotion and exploration (Karlsson et al.,
2008; Chatterjee et al., 2011).
Based on their pharmacokinetic properties (Kathuria et al.,
2003; Patel and Hillard, 2006), the drugs were administered
30 min before S3 of the A/A Y-Maze and S1of the OF task. Two
weeks later, the animals were reinjected with the same drugs that
they had received and sacrificed 30 min later to take electrophysio-
logical recordings (ER) of the striatal activity. The experimenters
that performed the behavioral testing and ER were blind to the
drug treatment.
STATISTICAL ANALYSIS
Data were presented as mean ± SEM and tested for normality
(Will-Shapiro’s test) and homoscedasticity (Levene’s test). Behav-
ioral data were compared by ANOVAs, followed by Tukey’s HSD
test, when appropriate.
Electrophysiological data were compared by paired or
unpaired Student’s t-test.
All analyses were performed using Statistica 7.0 for Windows,
and differences were considered significant at p ≤ 0.05.
RESULTS
BEHAVIORAL EFFECTS OF DRUGS ACTING ON THE ENDOCANNABINOID
AND DOPAMINERGIC SYSTEMS
A/A Y-Maze
The A/A Y-Maze required animals to choose between two con-
flicting drives, reaching a palatable reward in an aversive (white
and lighted) arm or standard food in a reassuring (black and dark)
arm. When white choice frequency was analyzed (Figure 2A) by
two-way ANOVA (drug× session), there was significant effects of
drug (F(5,54) = 2.66; p = 0.03) and session (F(2,108) = 147.83; p <
0.00001). Also, their interaction was significant (F(10,108) = 10.22;
p < 0.00001). Post hoc comparisons on the interaction revealed
that the white arm in S1 was chosen least often by the animals of
all groups. The frequency of white choices significantly (at least
p = 0.02) increased in S2.
Between S2 and S3 the VHL group significantly (p = 0.006)
increased their white choice. This response was expected, based
on the anxiolytic and familiarization effects with the experimental
apparatus with subsequent sessions. The URB group also sig-
nificantly (p = 0.0001) chose the white arm more frequently,
whereas the AM, URB+AM, and HAL groups did not. Thus,
CB1 and DAergic antagonists impeded the increased choice of the
white arm.
Notably, in URB+HAL group the coadministration of drugs
significantly (p = 0.0001) increased the frequency of white choices
to the same extent as in the URB group. Post hoc comparisons
relative to the intergroup differences in S3 are reported in the
Figure 2A.
With regard to entry latency (Figure 2B), by two-way ANOVA
(drug × session), there were significant drug (F(5,54) = 6.87; p =
0.00005) and session (F(2,108) = 14.02; p = 0.000004) effects. Also,
their interaction was significant (F(10,108) = 15.57; p < 0.00001).
By post hoc comparisons on interaction, there were no significant
differences in latency values between S1 and S2.
In S3, the HAL group had the highest latency values compared
with the other groups (all p = 0.0001)—when they stood still, they
were in stable equilibrium with a broad-based support and when
they were moving, they were slower to initiate (akinesia) and exe-
cute movements (bradykinesia). This significant motor slowdown
was mitigated in part by the coadministration of URB597 and
haloperidol. The URB+HAL group had significantly (p = 0.0001)
lower latency values than the HAL group, higher values than
the URB (p = 0.002) and VHL (p = 0.005) groups, and similar
values as the AM and URB+AM groups. Post hoc comparisons are
reported in the Figure 2B.
With regard to defecation boluses, two-way ANOVA (drug ×
session) indicated no significant drug (F(5,54) = 2.45; p = 0.06) and
session (F(2,108) = 1.25; p = 0.29) effect. Also, their interaction was
not significant (F(10,108) = 1.46; p = 0.16).
OF
The animals were tested in an OF, in which the conflicting
situation is represented by inserting an appealing new object
in the anxiogenic central location of a wide arena. Two-way
ANOVA (drug × session) on total distance traveled in the
absence (S1) and presence (S2) of the object revealed a significant
effect of drug (F(5,54) = 108.52; p < 0.00001) but not session
(F(1,54) = 1.86; p = 0.17). Their interaction was not significant
(F(5,54) = 1.42; p = 0.23). Post hoc comparisons on the drug
effect indicated that the haloperidol-dependent motor slowdown
in the A/A Y-Maze was present also in the OF task. Notably,
this effect was not relieved by the coadministration of URB597
and haloperidol–HAL and URB+HAL groups had similar dis-
tance values (p = 0.90). Both groups differed significantly from
the remaining groups (all p = 0.0001). Conversely, the AM,
URB, URB+AM, and VHL groups traveled similar distances
(Figure 3A).
A similar pattern emerged with regard to mean velocity. Two-
way ANOVA (drug × session) showed that drug had a significant
effect (F(5,54) = 81.16; p < 0.00001) but session did not (F(1,54) =
3.19; p = 0.08); their interaction was not significant (F(5,54) = 0.97;
p = 0.44). Post hoc comparisons on the drug effect remarked the
haperidol-dependent motor slowdown, which was not alleviated
by URB597 plus haloperidol; the HAL and URB+HAL groups
had similar velocity values (p = 0.95). Both groups differed
significantly from the remaining groups (all p = 0.0001); the
AM, URB, URB+AM, and VHL groups had similar velocities
(Figure 3B).
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FIGURE 2 | Behavioral effects of A/A Y-Maze. (A) Between S1 and S2,
all animals displayed a significant (at least p = 0.02, *) increase in white
choices. Between S2 and S3, the VHL (p = 0.006, **), URB (p = 0.0001,
***) and URB+HAL (p = 0.0001, ***) groups increased their white
choices, while the AM, URB+AM and HAL groups did not. The significant
post hoc comparisons of the intergroup differences in S3 were: URB (or
URB+HAL) vs. AM or HAL or URB+AM: p = 0.0002, ###; VHL vs. all the
other groups: at least p = 0.05, $. (B) Between S1 and S2, no significant
differences in entry latency were found. Between S2 and S3, the HAL
group had higher latency values (p < 0.0001, ***). In S3, the HAL group
showed highest entry latency values (vs. URB, URB+HAL, AM, URB+AM
groups at least p = 0.0001, +++; vs. VHL group p = 0.0001, $$$). The
haloperidol powerful effect was contrasted but not prevented by URB597
and haloperidol coadministration, as the URB+HAL group had higher
latency values than the URB (p = 0.002, ##) and VHL (p = 0.005, $$)
groups.
Two-way ANOVA (drug × session) on peripheral distance
revealed significant drug (F(5,54) = 4.10; p = 0.003) and session
(F(1,54) = 152.80; p < 0.00001) effects. Also, their interaction
was significant (F(5,54) = 2.80; p = 0.02). Post hoc comparison
on the interaction showed that all groups significantly (at least
p = 0.05) reduced peripheral distance, from 70% in S1 to 40%
of total distance in S2. This significant exploration of the central
sectors in the arena during S2 was related to the presence of
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FIGURE 3 | Behavioral effects of OF task. (A) Total distance, (B) velocity, (C)
freezing times and (D) contact times in the absence (S1) and presence (S2) of
the object. Note the haloperidol-dependent motor inhibition that was not
contrasted (or only partially with regard to freezing times) by URB597 and
haloperidol coadministration. In S1 and S2, the HAL group had the highest
freezing times (vs. URB, URB+HAL, AM, URB+AM groups at least p = 0.01,
+; vs. VHL group p = 0.001, $$). The URB+HAL group had freezing times
higher than URB, AM, URB+AM (p = 0.001, ##) and VHL (p = 0.001, $$)
groups. In (D), the URB group displayed the highest contact times (vs.
URB+HAL, URB+AM, HAL, AM groups at least p = 0.01, #; vs. VHL group
p = 0.05, $). All groups exhibited contact times significantly (at least p = 0.04,
$) lower than the VHL group.
the new object and indicated that all groups had similar anxiety
levels.
Two-way ANOVA (drug× session) on freezing times indicated
that the effects of drug (F(5,54) = 83.48; p < 0.00001), session
(F(1,54) = 3.79; p = 0.05), and their interaction were significant
(F(5,54) = 2.77; p = 0.02). Post hoc comparisons on interaction also
showed the significant haloperidol-dependent motor inhibition.
The HAL group had the highest freezing times in S1 (at least p =
0.01) and S2 (all p = 0.0001), an effect that was partially mitigated
by the coadministration of URB597 and haloperidol. In S1 and S2,
the URB+HAL group had significantly lower freezing times than
the HAL group, although significantly (all p = 0.0001) higher than
the other groups (Figure 3C).
For defecation boluses, two-way ANOVA (drug × session)
revealed no significant drug (F(5,54) = 2.03; p = 0.08) or session
(F(1,54) = 1.35; p = 0.31) effect. Their interaction was not signifi-
cant (F(5,54) = 1.96; p = 0.46).
One-way ANOVA on contact times revealed a significant drug
effect (F(5,54) = 15.62; p< 0.00001). Post hoc comparisons showed
that the URB group had the highest contact times compared with
all groups (at least p = 0.05). This effect was negated by the action
of CB1 inverse agonist, AM251. The AM and URB+AM groups
had similar contact times, which were significantly (at least p =
0.01) lower than in the VHL group. Also, the HAL and URB+HAL
groups had similar contact times that were significantly (p = 0.04)
lower than in the VHL group (Figure 3D). Thus, the decreased
activity of CB1 receptors by AM251 (alone or with URB597) or of
D2 receptors by haloperidol (alone or with URB597) inhibited the
response to novelty.
ELECTROPHYSIOLOGICAL EFFECTS OF DRUGS ACTING ON THE
ENDOCANNABINOID AND DOPAMINERGIC SYSTEMS
Stimulation of CB1 receptors by HU210 significantly inhibited
striatal GABAergic sIPSCs in the VHL group (n = 9, p< 0.01). In
vivo treatment with AM251 failed to alter per se sIPSC frequency
(n = 12, p > 0.05 compared with the VHL group before HU210)
(data not shown) but suppressed the effects of HU210 (n= 10, p>
0.05). This effect was also present in the URB+AM group (n = 11,
p > 0.05). Haloperidol blocked the effects of HU210 on striatal
GABAergic synapses (n = 6, p > 0.05). Notably, CB1 receptor
sensitivity was rescued by coadministration of haloperidol and
URB597 (n = 8, p < 0.05), although URB597 alone did not
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FIGURE 4 | Electrophysiological effects. Stimulation of CB1 receptors
with HU210 caused inhibition of striatal GABAergic sIPSCs in the VHL
group. AM251 (alone or with URB597) and haloperidol treatments resulted
in the suppression of HU210 effects. CB1 receptor sensitivity was rescued
when haloperidol and URB597 were coadministered, although URB597
alone did not increase HU210 effects.
increase per se the HU210 effects on sIPSCs (n = 6, p < 0.01
compared with the pre-HU210 value and p n.s. compared with
effect of HU210 in the VHL group) (Figure 4).
DISCUSSION
In the behavioral tests that we administered, there was a conflict
between positive and negative drives; thus, approach and avoid-
ance behaviors were evoked simultaneously. Typically, when these
trends have similar strength, the subject remains suspended or, at
best, tends to gravitate toward the heavier pole of the conflicting
situation. When the subject is re-exposed to the same conflicting
situation, the anxiogenic components tend to fade, and the more
appealing pole of the conflicting situation is reached more easily.
These reasons are why the control animals (VHL group) moved
slightly toward the appetitive (palatable food or new object) pole
and increased the responses to reward when re-exposed to the task
in the A/A Y-Maze.
The main finding of this study was that CB1-mediated pro-
cesses and their interaction with DAergic transmission mod-
ulated the salience of reward. In S3 of the A/A Y-Maze and
in the OF task, animals that were treated with URB597, a
drug that potentiates endocannabinoid activity through anan-
damide increase, had a robust approach behavior toward palat-
able food and the new object. Notably, AM251, a CB1 inverse
agonist, alone and in combination with URB597, blocked the
approach behavior, demonstrating that the effect of URB597
on such behavior is mediated by CB1 receptors. Recently, the
orphan G-Protein coupled Receptor, GPR55, has been presented
as a candidate of cannabinoid receptor subtypes (Ryberg et al.,
2007; Lauckner et al., 2008). The GPR55 recognizes cannabi-
noids, but it differs from CB1 receptor. Some cannabinoids have
high affinity for the GPR55 receptor and in low doses can
play as an agonist for this receptor. Also the AM251 behaves
as an agonist with high affinity for GPR55 receptor (Ryberg
et al., 2007). Therefore, in the present study the blockade of
the approach behavior observed in the presence of AM251
administration could be related also to the activity of the GPR55
receptors.
CB1 are expressed in several reward-related brain areas, such
as the substantia nigra, ventral tegmental area, dorsal and ven-
tral striatum, prefrontal cortex, and corticolimbic structures that
receive collateral DAergic innervations (Marsicano and Lutz,
1999; Hermann et al., 2002). Specifically, in the dorsal striatum,
CB1 expression is significant in medium spiny neurons that
receive DAergic inputs and express D1 and D2 receptors (Monory
et al., 2007). Striatal DA efflux rises when anandamide levels are
upregulated by URB597 (Solinas et al., 2006). However, in striatal
slice preparations, CB1 receptor activation has no effect on DA
release (Köfalvi et al., 2005), suggesting that CB1 regulation of DA
release involves a multisynaptic mechanism (Riegel and Lupica,
2004; Marinelli et al., 2007).
The administration of haloperidol (D2 antagonist) blocked
approach behavior, like AM251 did. However, whereas AM251
did not influence motor function, haloperidol impaired locomo-
tor activity. Consistent with this observation, much evidence indi-
cates that this neuroleptic drug causes dose-dependent akinesia
and muscle rigidity (De Ryck et al., 1980; Lorenc-Koci et al., 1996;
Ozer et al., 1997).
Coadministration of URB597 and haloperidol counteracted
the effects of haloperidol on approach behavior and motor activ-
ity. Notably, the effect of ECS potentiation, combined with D2
receptor blockade, developed only when the reward was repre-
sented by palatable food. Such a facilitatory effect on food rein-
forcement appeared to be due to the higher salience of palatable
food, based on the hedonic properties of its palatability, compared
with the lower salience of the object, regardless of its novelty. The
regulation of DAegic processes by the striatal ECS is central to the
hedonic aspects of food-seeking (Duarte et al., 2004), food novelty
(Bassareo et al., 2002), and need state with regard to hunger (De
Luca et al., 2012). CB1 antagonists decrease and CB1 agonists
increase DA release that is induced by rewarding stimuli (Cohen
et al., 2002; Fadda et al., 2006; Solinas et al., 2006).
In this study, the combination of URB597 and haloperidol
affected motor activity. Although slackened, URB+HAL-treated
animals had lower entry latencies in the A/A Y-Maze but remained
inhibited in the OF task, as evidenced by their total distance and
velocity values. Such dissociation between behaviors in the tasks
suggests that the reduction in entry latency values in the A/A
Y-Maze was a food-dependent effect. The motor slowdown that
was evoked by the D2 antagonist was mitigated in the URB+HAL
group only when stimulus salience was high, as for palatable food.
Likely, the haloperidol increases the amount of glutamate that is
released from corticostriatal neurons by counteracting the DA-
dependent inhibition of this release, which in turn stimulates
striatopallidal output neurons and renders the animal akinetic
with muscle rigidity (Yoshida et al., 1994).
It has been suggested that NMDA antagonists alleviate motor
slowdown by suppressing the excessive cortical stimulation of
the striatopallidal pathway at the level of the striatum (Kaur
et al., 1997). Thus, in the URB+HAL group, the partial motor
recovery might be linked to the ability of URB597 to potentiate
endocannabinoid tone, which in turn activates CB1 receptors that
presynaptically inhibit striatal glutamatergic neurotransmission.
Frontiers in Behavioral Neuroscience www.frontiersin.org May 2014 | Volume 8 | Article 183 | 7
Laricchiuta et al. Endocannabinoids, dopamine and reward
This proposal is supported by Giuffrida et al. (1999), who demon-
strated that motor activity increases anandamide dorsostriatal
release after administration of a D2 agonist, a response that
is prevented by a D2 antagonist. Further, D1 agonists did not
change the basal outflow of anandamide, underscoring the dif-
ferences between D1 and D2 agonists with respect to anandamide
release.
Notably, blockade of CB1 activity has opposite effects on
psychostimulant-induced hyperactivity (Poncelet et al., 1999).
Conversely, inhibitors of the anandamide reuptake or of FAAH
attenuate the hyperactivity in hyperdopaminergic mice (Tzavara
et al., 2006). Hyperactivity also decreases in response to d-
amphetamine treatment in CB1 knockout mice (Tzavara et al.,
2009).
Because the behavioral tests of this study integrated an
approach-avoidance conflict (reward searching or exploratory
drive against brightly lit or open space), the inevitable anxiogenic
component that is linked to the conflict must be considered. At
least two factors can influence anxiety-like behavior in the A/A Y-
Maze and OF tasks: social isolation of the single specimen, result-
ing from physical separation from cage mates when performing
the test, and the aversive feature that is created by the brightly
lit, unprotected, novel environment. Thus, both tests can be used
to screen for anxiety-related behaviors and analyze the impact of
drugs on them.
Drugs that target the ECS elicit anxiolytic or anxiogenic
actions. Specifically, in various anxiety paradigms, URB597 has
anxiolytic effects (Patel and Hillard, 2006; Moreira et al., 2008;
Rubino et al., 2008; Scherma et al., 2008), depending largely
on the stress conditions of the experimental protocols, provided
that the conditions do not exceed the ECS buffering function
(Naidu et al., 2007; Haller et al., 2009). These findings indicate
tonic modulation of aversive responses, based on the approach-
avoidance conflict. Further, CB1 receptor agonists induce biphasic
effects, wherein lower doses are anxiolytic and higher doses are
anxiogenic (Viveros et al., 2005). AM251 has an anxiogenic effect
when injected at high (3.0 mg/kg) doses and reverses URB597-
induced anxiolytic and panicolytic effects (Gobira et al., 2013).
In this study, all groups that were treated with drugs that act
on the ECS and DAergic system had similar anxiety levels as
the VHL group, based on analysis of primarily anxiety-related
parameters—e.g., A/A Y-Maze and OF defecation boluses and
OF peripheral distance (thigmotaxis). With regard to OF freezing
times, whereas animals that were given ECS-targeted drugs had
similar values, the HAL and URB+HAL groups had significantly
higher freezing times. However, this increase can not be consid-
ered an index of merely enhanced anxiety, because it was heav-
ily influenced by the confounding factor haloperidol-dependent
motor slowdown. These findings are consistent with the hypothe-
sis that a fear/anxiety state does not underlie haloperidol-induced
catalepsy (Colombo et al., 2013). Similarly, there is no evidence of
a relationship between catalepsy and fear/anxiety state in congenic
mouse strains (Kondaurova et al., 2011).
Our electrophysiological results complement our behavioral
findings. In the VHL and URB groups, stimulation with HU210
(CB1 agonist) inhibited GABAergic dorsostriatal neurotransmis-
sion, consistent with previous reports (De Chiara et al., 2010b;
Laricchiuta et al., 2012b). In rodents, manipulations with strong
reinforcing properties, such as cocaine-induced conditioned place
preference, spontaneous running wheel activity, and sucrose con-
sumption, are associated with hypersensitivity of dorsostriatal
GABAergic synapses to CB1 stimulation (Centonze et al., 2007a,b;
De Chiara et al., 2010b). In a recent study (Laricchiuta et al.,
2012b), we reported that enhanced or reduced CB1-mediated
control over GABAergic dorsostriatal neurotransmission was
associated with spontaneous approach or avoidance behavior
toward or away from palatable food, respectively. Further, CB1
activation on GABAergic or glutamatergic neurons has opposite
effects on exploratory activity (Häring et al., 2011).
In this study, the administration of the CB1 inverse agonist
AM251 (alone or with URB597) or the D2 antagonist haloperidol
suppressed the effects of HU210 on GABAergic dorsostriatal
transmission. These findings are consistent with the observation
that D2 stimulation activates the dorsostriatal ECS, influencing
GABAergic synapses (Centonze et al., 2004, 2007a,b). Notably, in
our study, CB1 receptor sensitivity to HU210 was rescued when
URB597 and haloperidol were coadministered.
Overall, our behavioral and electrophysiological results
demonstrated that by increasing anandamide levels, endo-
cannabinoid potentiation magnified the search for reward and,
in parallel, inhibited dorsostriatal GABAergic neurotransmis-
sion. Blockade of CB1 or D2 receptors inhibited reward-related
responses and prevented the inhibition of dorsostriatal GABAer-
gic neurotransmission. Notably, the reward-related response was
restored when the blockade of DAergic activity was combined
with ECS potentiation. This effect occurred only if the reward was
palatable food. Accordingly, the coadministration of URB597 and
haloperidol restored the dorsostriatal responses to stimulation
with HU210.
Although the use of single doses of drugs might be a limi-
tation in interpreting behavioral and electrophysiological effects
we found, it has to be underlined that our results are fully
consistent with the hypothesis that endocannabinoids control
the reward-related processes and are also implicated in reward-
related disorders. Endocannabinoid and DAergic transmission
might interact functionally to modulate salient information pro-
cessing. Abnormalities in the neural mechanisms that govern
reward-related processes might underlie the aberrant emotional
processing in such disorders as schizophrenia and addiction
(Ziauddeen and Murray, 2010; Gardner, 2011). The increase in
anandamide in schizophrenic patients might constitute a com-
pensatory response to counteract primary DAergic dysfunction
(Giuffrida et al., 2004), advancing the therapeutic potential of the
ECS in DA-related disorders. Thus, new insight into ECS activity
in reward-related DAergic circuitry should guide the development
of pharmacological treatments for eating, drug abuse, and psychi-
atric disorders.
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